A
ASCO Intelligence
Annual Meeting · 2026
Overview
Explore
Ask
Methodology
CT
Local
Sign in
Explore the programme
Three lenses on the same data - schedule, topic network, and KOL alignment.
Schedule swimlanes
Posters
Topic constellation
KOL alignment matrix
Fri, May 29
Sat, May 30
Sun, May 31
Mon, Jun 1
Tue, Jun 2
Time TBA
KOL-matched only
All tracks
Breast Cancer—Local/Regional/Adjuvant
Breast Cancer—Metastatic
Care Delivery/Models of Care
Central Nervous System Tumors
Developmental Therapeutics—Immunotherapy
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Gastrointestinal Cancer—Colorectal and Anal
Gastrointestinal Cancer—Gastroesophageal
Genitourinary Cancer—Kidney and Bladder
Genitourinary Cancer—Prostate
Gynecologic Cancer
Head and Neck Cancer
Hematologic Malignancies—Leukemia
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Hematologic Malignancies—Plasma Cell Dyscrasia
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Lung Cancer—Non-Small Cell Metastatic
Medical Education and Professional Development
Melanoma/Skin Cancers
Pediatric Oncology
Prevention
Quality Care/Health Services Research
Sarcoma
Special Sessions
Symptom Science and Palliative Care
All session types
Rapid Oral Abstract Session (216)
Oral Abstract Session (201)
Clinical Science Symposium (44)
Plenary Session (5)
67 sessions · 8 lanes
Track
13:00
14:00
15:00
16:00
17:00
18:00
Care Delivery/Models of Care
Genitourinary Cancer—Kidney and Bladder
Gynecologic Cancer
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Hematologic Malignancies—Plasma Cell Dyscrasia
Lung Cancer—Non-Small Cell Metastatic
Medical Education and Professional Development
Pediatric Oncology
Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
13:00 CT
First-line odronextamab (Odro) plus chemotherapy (CHOP) in diffuse large B-cell lymphoma (DLBCL): OLYMPIA-3 Part 1B results.
13:00 CT
Real-world outcomes of bispecific antibodies in relapsed/refractory (R/R) follicular lymphoma (FL).
13:06 CT
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results.
13:12 CT
Overall survival of first-line amivantamab plus lazertinib in atypical <em>EGFR</em>-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.
13:12 CT
Wait or treat? managing asymptomatic brain metastases in oncogene-mutated NSCLC: Results of a phase-III randomized controlled trial.
13:24 CT
Safety and efficacy of Azer-cel, an allogeneic CD19 CAR T for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia not previously exposed to autologous CAR T therapy.
13:30 CT
REVO-U: A next-generation, gene-editing–free universal CAR-T platform to enable ultra–high-yield manufacturing and identification of early clinical activity in relapsed/refractory DLBCL.
13:36 CT
First-in-human in vivo CAR T-cell generation using a CD8-targeted lipid nanoparticle platform in relapsed/refractory B-cell lymphoma.
13:42 CT
Lorlatinib vs crizotinib as first-line treatment for advanced <em>ALK</em>+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
14:00 CT
First-in-human novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies.
14:00 CT
Genetic signatures of CNS relapse in DLBCL patients profiled with next-generation sequencing (NGS).
14:06 CT
ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced <em>ALK</em>+ NSCLC.
14:12 CT
Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial.
14:12 CT
Efficacy and safety of pralsetinib as first-line treatment of <em>RET</em> fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
14:24 CT
Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced <em>RET </em>fusion–positive non–small cell lung cancer (NSCLC).
14:36 CT
A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
14:45 CT
Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.
14:45 CT
Randomized controlled trial of a psychosocial digital application (THRIVE-MM) for patients living with multiple myeloma.
14:45 CT
Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
14:45 CT
Analyzing county-level factors of oncology fellowship program development from 2015-2025.
14:45 CT
Use of a patient-facing digital tool for glioblastoma outside scheduled clinic visits.
14:51 CT
Projecting 2050 oncology workforce through historical regional trends and economic stratification.
14:51 CT
A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma.
14:57 CT
Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
14:57 CT
Telehealth visits to support extended dosing of pembrolizumab and reduce health care visits: A pragmatic trial.
14:57 CT
Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.
14:57 CT
Support of academic non-clinical efforts for cancer investigator faculty at Association of American Cancer Institutes.
14:57 CT
ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.
15:09 CT
First results from the phase 1/2 LINKER-AL2 trial of linvoseltamab (LINVO) in patients (pts) with relapsed or refractory (RR) systemic light chain (AL) amyloidosis.
15:09 CT
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
15:12 CT
Addressing geographic disparities in cancer care: An examination of the contributions of international medical graduates (IMGs).
15:15 CT
Gender representation in first and senior authorship of phase III solid-tumor trials presented at the ASCO Annual Meeting, 2015-2025.
15:15 CT
Evaluation and appraisal of quality indicators for end-of-life cancer care in an African context.
15:21 CT
Understanding the impact of gold and silver signals on ERAS applications: A survey of hematology/oncology fellowship program directors.
15:21 CT
A randomized, open-label, parallel-controlled phase 3 trial of benmelstobart plus chemotherapy and anlotinib for first-line treatment of advanced non-squamous non–small cell lung cancer.
15:24 CT
Advancing career-focused training: Program leader perspectives on professional development pathways in hematology/oncology fellowships.
15:27 CT
Timing of telepalliative care and end-of-life outcomes in advanced cancer: A multicenter retrospective cohort study.
15:27 CT
Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
15:33 CT
A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer.
15:45 CT
Intravesical recombinant BCG combined with chemo-immunotherapy (chemo-IO) as perioperative therapy for patients with muscle-invasive bladder cancer (MIBC): Primary analysis of SAKK 06/19.
15:45 CT
Career fulfillment and intent to leave among oncology physicians: A global survey.
15:45 CT
DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).
15:45 CT
LLM-generated serious illness conversation summaries to improve care for hospitalized patients: A pilot clinical trial.
15:45 CT
Effect of a financial navigation intervention on financial toxicity among patients with breast cancer: A randomized controlled trial in China.
15:51 CT
Burnout (BO) among oncology professionals in the Middle East and North Africa (MENA): Meta-analysis of pre–post COVID trends, contributors, and predictive value of single-item screening tool.
15:51 CT
Effect of group community health worker–led advance care planning education on advance care planning documentation, satisfaction, palliative care, and hospice: Results from a randomized clinical trial.
15:57 CT
Impact of sustained MRD negativity for up to 5 years on long-term outcome of transplant-eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase 2 FORTE trial.
15:57 CT
Standardized mean differences of primary outcomes found in randomized controlled trials of wellness interventions among medical trainees: A systematic review and meta-analysis.
15:57 CT
Health-related quality of life (HRQOL) with pembrolizumab or observation for high-risk muscle-invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501).
15:57 CT
CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer.
15:57 CT
New IMS/IMWG risk criteria by next-generation sequencing (NGS): Analysis of daratumumab benefit in both high- and standard-risk patients (pts) in the PERSEUS study.
16:09 CT
Primary breast malignancies in adolescents and young adults: The MD Anderson Cancer Center experience.
16:30 CT
Perioperative SHR-A2102, a novel nectin-4–targeted antibody-drug conjugate, in combination with adebrelimab for patients (pts) with muscle-invasive bladder cancer: Results from a phase 2/3 study.
16:33 CT
A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
16:33 CT
Characteristics and survival of 4N and non-4N metastatic neuroblastoma across treatment eras: A report from the International Neuroblastoma Risk Group Task Force.
16:36 CT
Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
16:45 CT
Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
16:45 CT
Updated efficacy results from the phase I cervical cancer cohort of BAT8008, a TROP-2–directed antibody-drug conjugate, in patients with advanced cervical cancer.
16:45 CT
Real-world experience of a pediatric precision oncology protocol utilizing paired somatic and germline sequencing at a single institution: Interim analysis.
16:57 CT
Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
16:57 CT
A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer.
16:57 CT
MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).
16:57 CT
Harnessing OMOP-CDM for multisite collaborations to measure cardiovascular risk factors and cardiovascular disease in the early survivorship period for children, adolescents, and young adults.
17:03 CT
Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.
17:09 CT
Association of neighborhood-level vulnerability with health behavior patterns in survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE).
17:24 CT
Thematic game intervention as a novel psychosocial support to reduce sedation needs and anxiety in pediatric neuro-oncology patients during radiotherapy: A prospective cohort study (2020–2025).
17:30 CT